Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne.

The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line. [ABSTRACT FROM AUTHOR]